3SBio Inc.

SEHK:1530 Stock Report

Market Cap: HK$72.7b

3SBio Valuation

Is 1530 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 1530 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

HK$52.21
Fair Value
41.8% undervalued intrinsic discount
11
Number of Analysts

Below Fair Value: 1530 (HK$30.4) is trading below our estimate of fair value (HK$52.21)

Significantly Below Fair Value: 1530 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 1530?

Key metric: As 1530 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 1530. This is calculated by dividing 1530's market cap by their current earnings.
What is 1530's PE Ratio?
PE Ratio28.2x
EarningsCN¥2.36b
Market CapCN¥66.54b

Price to Earnings Ratio vs Peers

How does 1530's PE Ratio compare to its peers?

The above table shows the PE ratio for 1530 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average54.1x
2696 Shanghai Henlius Biotech
44.3x3.66%HK$39.9b
1801 Innovent Biologics
135.6x32.81%HK$167.8b
6826 Shanghai Haohai Biological Technology
13.7x14.31%HK$11.8b
2142 HBM Holdings
22.6x-25.46%HK$12.9b
1530 3SBio
28.2x-11.00%HK$72.7b

Price-To-Earnings vs Peers: 1530 is good value based on its Price-To-Earnings Ratio (28.2x) compared to the peer average (54.1x).

Price to Earnings Ratio vs Industry

How does 1530's PE Ratio compare vs other companies in the Asian Biotechs Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
1530 28.2xIndustry Avg. 44.7xNo. of Companies13PE020406080100+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 1530 is good value based on its Price-To-Earnings Ratio (28.2x) compared to the Asian Biotechs industry average (44.7x).

Price to Earnings Ratio vs Fair Ratio

What is 1530's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

1530 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio28.2x
Fair PE Ratio23.8x

Price-To-Earnings vs Fair Ratio: 1530 is expensive based on its Price-To-Earnings Ratio (28.2x) compared to the estimated Fair Price-To-Earnings Ratio (23.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 1530 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentHK$30.40
HK$37.59
+23.64%
15.64%HK$46.30HK$25.20n/a11
Sep ’26HK$29.96
HK$34.77
+16.07%
23.16%HK$46.36HK$21.27n/a11
Aug ’26HK$30.20
HK$31.41
+4.00%
27.36%HK$45.50HK$19.68n/a10
Jul ’26HK$23.65
HK$21.14
-10.61%
33.17%HK$30.02HK$9.30n/a9
Jun ’26HK$18.82
HK$19.86
+5.55%
33.21%HK$28.30HK$9.22n/a8
May ’26HK$11.96
HK$12.07
+0.95%
21.25%HK$17.00HK$8.70n/a9
Apr ’26HK$13.06
HK$11.53
-11.73%
17.54%HK$14.20HK$8.69n/a8
Mar ’26HK$7.34
HK$8.39
+14.31%
16.97%HK$11.02HK$6.34n/a8
Feb ’26HK$6.01
HK$8.40
+39.76%
17.05%HK$11.05HK$6.36n/a8
Jan ’26HK$6.08
HK$8.28
+36.12%
17.35%HK$10.94HK$6.30n/a8
Dec ’25HK$5.72
HK$7.96
+39.11%
15.94%HK$9.99HK$6.18n/a9
Nov ’25HK$5.86
HK$7.96
+35.79%
15.94%HK$9.99HK$6.18n/a9
Oct ’25HK$6.87
HK$8.02
+16.79%
15.94%HK$10.08HK$6.23HK$30.009
Sep ’25HK$6.06
HK$8.02
+32.40%
15.94%HK$10.08HK$6.23HK$29.969
Aug ’25HK$6.04
HK$7.56
+25.22%
17.70%HK$9.98HK$6.15HK$30.207
Jul ’25HK$6.44
HK$7.49
+16.26%
17.90%HK$10.00HK$6.14HK$23.657
Jun ’25HK$6.10
HK$7.46
+22.23%
16.46%HK$9.59HK$6.17HK$18.827
May ’25HK$6.28
HK$7.46
+18.72%
16.46%HK$9.59HK$6.17HK$11.967
Apr ’25HK$5.98
HK$7.53
+25.86%
16.42%HK$9.60HK$6.17HK$13.067
Mar ’25HK$5.62
HK$8.19
+45.67%
13.00%HK$9.70HK$6.30HK$7.347
Feb ’25HK$6.02
HK$8.67
+44.01%
8.52%HK$9.80HK$7.71HK$6.017
Jan ’25HK$7.52
HK$8.67
+15.29%
8.52%HK$9.80HK$7.71HK$6.087
Dec ’24HK$7.51
HK$8.47
+12.79%
8.18%HK$9.52HK$7.65HK$5.727
Nov ’24HK$6.95
HK$8.47
+21.87%
8.18%HK$9.52HK$7.65HK$5.867
Oct ’24HK$6.55
HK$8.30
+26.70%
9.85%HK$9.55HK$6.98HK$6.878
HK$37.59
Fair Value
19.1% undervalued intrinsic discount
11
Number of Analysts

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/04 16:56
End of Day Share Price 2025/10/03 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

3SBio Inc. is covered by 37 analysts. 14 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Difei YangCapstone Investments
Bo YuChina International Capital Corporation Limited
Zhuhong ChenChina Merchants Securities (HK) Co., Ltd